{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-24-058194","form_type":"8-K","ticker":"TCRX","cik":"0001783328","company_name":"TScan Therapeutics, Inc.","filed_at":"2024-05-13T23:59:59+00:00","discovered_at":"2026-05-14T18:03:20.081272+00:00","generated_at":"2026-06-02T02:35:25.571415+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"TScan reports Q1 2024 results: net loss $30.1M, first solid tumor patient dosed, heme patients relapse-free","bullets":["Net loss of $30.1M for Q1 2024 compared to $22.6M in Q1 2023; revenue fell to $0.6M from $6.8M.","First patient dosed in Phase 1 solid tumor trial with TSC-203-A0201 targeting PRAME; initial data expected H2 2024.","All eight heme treatment-arm patients relapse-free with median follow-up >10 months; two control patients relapsed.","Closed upsized $167.8M public offering in April; cash and marketable securities $162.8M at March 31, extending runway to Q4 2026."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-24-058194","json":"https://secwatch.observer/filing/0000950170-24-058194.json","markdown":"https://secwatch.observer/filing/0000950170-24-058194.md","text":"https://secwatch.observer/filing/0000950170-24-058194.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1783328/000095017024058194/0000950170-24-058194-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1783328/000095017024058194/tcrx-20240513.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-02T02:35:25.571415+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"fb42a5f597c5f9995a8a2dc806dc8074650819fb","claim":"TScan Therapeutics, Inc. reported the first quarter ended March 31, 2024 results: revenue $0.6 million.","evidence_excerpt":"• Long-term duration of response data for multiplex therapy anticipated in 2025. First Quarter 2024 Financial Results Revenue: Revenue for the first quarter of 2024 was $0.6 million, compared to $6.8 million for the first quarter of 2023. The decrease was primarily due to the timing of research activities pursuant to the Company’s collaboration agreements.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1783328/000095017024058194/0000950170-24-058194-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the first quarter ended March 31, 2024"},{"label":"Revenue","value":"$0.6 million"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}